Cetrotide
(cetrorelix)ApprovedSmall molecule
EMD SeronoCetrorelix is used to prevent premature ovulation in women undergoing fertility treatments like in vitro fertilization (IVF). It helps control the timing of egg release so doctors can retrieve eggs at the optimal moment for the procedure.[2] Cetrotide is currently approved and in use across 4 indications[4].[1]
Cetrotide is one of 119 small molecule programs targeting Benign Prostatic Hyperplasia. It is currently in Approved.
4
Indications
27
Total Trials
2
Active Trials
118
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
190 competitors in Obesity
#DrugCompanyPhaseTrials
1Cetrotide
EMD SeronoApproved
Cagrilintide
Novo NordiskPhase 3
Retatrutide
Eli LillyPhase 3
Enavogliflozin
Daewoong Pharmaceutical Co. LTD.Phase 3
Gemtesa
Sumitomo Pharma America, Inc.Phase 3
Berobenatide
PfizerPhase 3
Ribupatide
KKailera
Phase 3
Elecoglipron
AstraZenecaPhase 3
Survodutide
Boehringer IngelheimPhase 3
Avapro
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
GnRH Antagonist4 trials
Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI
Completed·—·Phase 4·NCT04724486·50 enrolled
Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes.
Completed·—·Phase 4·NCT04724343·50 enrolled
Ovarian Hyperstimulation Syndrome3 trials
Gonadotropin Releasing Hormone Antagonist in Treatment of Early-onset Severe Ovarian Hyperstimulation Syndrome
Completed·—·Phase 2·NCT02784457·84 enrolled
Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome
Unknown status·—·Phase 2/3·NCT02823080·48 enrolled
Polycystic Ovary Syndrome3 trials
Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology in Polycystic Ovary Syndrome Patients During IVF/ICSI
Completed·—·Phase 4·NCT04727684·50 enrolled
Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients.
Completed·—·Phase 4·NCT04727671·50 enrolled
Obesity2 trials
12 more indications
Ovarian Hyperstimulation2 trials
Cystic1 trial
Comparison Between Two Different Protocols in Polycystic Ovary Symdrome Women Undergoing Intra-cytoplasmic Injection
Unknown status·—·Phase 4·NCT04094467·150 enrolled
Progesterone1 trial
Endometriosis1 trial
Rheumatoid Arthritis1 trial
Gonadotropin-Releasing Hormone (GnRH)-Antagonist Therapy in Rheumatoid Arthritis
Completed·—·Phase 2·NCT00667758·104 enrolled
In Vitro Fertilization1 trial
Progesterone Primed Ovarian Stimulation Versus GnRH Antagonist in With Expected High Ovarian Response Undergoing in Vitro Fertilization
Unknown status·—·Phase 2/3·NCT05951400·200 enrolled
Clinical Trial1 trial
Hypertrophy1 trial
TIA1 trial
Fixed Versus Flexible Gonadotropin-releasing Hormone (GnRH) Antagonist Initiation
Completed·—·Phase 4·NCT01005784·146 enrolled
Embryo Transfer1 trial
Long Protocol and Freeze All Embryos vs Antagonist Protocol With Fresh Embryo Transfer in PCOS Patients Undergoing ICSI
Completed·—·Phase 4·NCT03118830·204 enrolled
Regulatory
FDA Approval Timeline[5]
Aug 11, 2000
CETROTIDE
NDA NDA021197
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Cetrotide drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for cetrorelix. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Gonadotropin-Releasing Hormone Receptor Antagonist[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company